Yogic versus conventional treatment in diarrhea-predominant irritable bowel syndrome: A randomized control study

被引:69
|
作者
Taneja, I
Deepak, KK [1 ]
Poojary, G
Acharya, IN
Pandey, RM
Sharma, MP
机构
[1] All India Inst Med Sci, Dept Physiol, New Delhi 110029, India
[2] All India Inst Med Sci, Cent Council Res Yoga & Naturopathy, New Delhi, India
[3] All India Inst Med Sci, Dept Biostat, New Delhi, India
[4] All India Inst Med Sci, Dept Gastroenterol, New Delhi, India
关键词
diarrhea-predominant irritable bowel syndrome; yogic intervention; autonomic functions; bowel symptoms; electrogastrography;
D O I
10.1023/B:APBI.0000017861.60439.95
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
This study was conducted to evaluate the comparative effect of yogic and conventional treatment in diarrhea-predominant irritable bowel syndrome (IBS) in a randomized control design. The patients were 22 males, aged 20-50 years, with confirmed diagnosis of diarrhea-predominant IBS. The conventional group (n = 12, 1 dropout) was given symptomatic treatment with loperamide 2-6 mg/day for 2 months, and the yogic intervention group ( n D 9) consisted of a set of 12 asanas ( yogic poses, i.e., Vajrasana, Shashankasana, Ushtrasana, Marjariasana, Padhastasana, Dhanurasana, Trikonasana in two variations, Pawanmuktasana, and Paschimottanasana) along with Surya Nadi pranayama ( right-nostril breathing) two times a day for 2 months. All participants were tested at three regular intervals, at the start of study - 0 month, 1 month, and 2 months of receiving the intervention - and were investigated for bowel symptoms, autonomic symptoms, autonomic reactivity ( battery of five standard tests), surface electrogastrography, anxiety profile by Spielberger's Self Evaluation Questionnaire, which evaluated trait and state anxiety. Two months of both conventional and yogic intervention showed a significant decrease of bowel symptoms and state anxiety. This was accompanied by an increase in electrophysiologically recorded gastric activity in the conventional intervention group and enhanced parasympathetic reactivity, as measured by heart rate parameters, in yogic intervention group. The study indicates a beneficial effect of yogic intervention over conventional treatment in diarrhea-predominant IBS.
引用
收藏
页码:19 / 33
页数:15
相关论文
共 50 条
  • [41] Targeting diarrhea-predominant irritable bowel syndrome: hopes or hypes?
    Bassotti, Gabrio
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2024,
  • [42] Decreased mucosal cytokines in diarrhea-predominant irritable bowel syndrome
    Chang, L
    Anton, P
    Elliott, J
    Reinholdt, J
    Taing, P
    Mayer, E
    GASTROENTEROLOGY, 2002, 122 (04) : A552 - A552
  • [43] RIFAXIMIN IS A SAFE THERAPY FOR DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME
    Weinstock, Leonard B.
    Pimentel, Mark
    Heimanson, Zeev
    Lembo, Anthony
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2018, 33 : S331 - S332
  • [44] Misinterpreting Diarrhea-Predominant Irritable Bowel Syndrome and Functional Diarrhea: Pathophysiological Highlights
    Sciume, Giusi Desire
    Berti, Ginevra
    Lambiase, Christian
    Paglianiti, Italia
    Villanacci, Vincenzo
    Rettura, Francesco
    Grosso, Antonio
    Ricchiuti, Angelo
    Bortoli, Nicola de
    Usai Satta, Paolo
    Bassotti, Gabrio
    Bellini, Massimo
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (18)
  • [45] Psychosocial determinants of rifaximin adherence for the treatment of diarrhea-predominant irritable bowel syndrome (IBS)
    Sherwin, L.
    Krisanabud, P.
    Deroche, C.
    Matteson-Kome, M.
    Ruppar, T.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2018, 30
  • [46] Review: The Role of MOP and DOP Receptors in Treatment of Diarrhea-predominant Irritable Bowel Syndrome
    Jarmuz, Agata
    Zielinska, Marta
    Len, Karolina
    Banaszek, Martyna
    Storr, Martin
    Fichna, Jakub
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2016, 16 (18) : 1462 - 1469
  • [47] Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome
    Lembo, Anthony
    Pimentel, Mark
    Rao, Satish S.
    Schoenfeld, Philip
    Cash, Brooks
    Weinstock, Leonard B.
    Paterson, Craig
    Bortey, Enoch
    Forbes, William P.
    GASTROENTEROLOGY, 2016, 151 (06) : 1113 - 1121
  • [48] Diarrhea-Predominant and Constipation-Predominant Irritable Bowel Syndrome: Current Prescription Drug Treatment Options
    Wechsler, Emily V.
    Shah, Eric D.
    DRUGS, 2021, 81 (17) : 1953 - 1968
  • [49] Diarrhea-Predominant and Constipation-Predominant Irritable Bowel Syndrome: Current Prescription Drug Treatment Options
    Emily V. Wechsler
    Eric D. Shah
    Drugs, 2021, 81 : 1953 - 1968
  • [50] Characterization of kynurenine pathway in patients with diarrhea-predominant irritable bowel syndrome
    Li, Pingping
    Zheng, Jimin
    Bai, Yun
    Wang, Dingxin
    Cui, Zijin
    Li, Yueqin
    Zhang, Jian
    Wang, Yuzhen
    EUROPEAN JOURNAL OF HISTOCHEMISTRY, 2020, 64 : 14 - 21